LDOS: Federal Health And Security Spending Will Drive Steady Performance Ahead

The updated analyst price target framework for Leidos Holdings edges lower, with fair value moving from $183.27 to $178.27 as analysts factor in recent downgrades, reduced targets tied to healthcare contract pressure, and more cautious assumptions for organic growth, margins, and future P/E.

Analyst Commentary

Recent Street research on Leidos Holdings has tilted more cautious, with several bearish analysts revisiting ratings and price targets as they reassess healthcare exposure, organic growth expectations, and earnings power. At the same time, there are still some bullish analysts who see upside based on current valuation and execution potential.

Bullish Takeaways

• Some bullish analysts initiating coverage with an Outperform rating and a US$165 price target suggest they see room for Leidos shares to trade above more conservative targets. This indicates confidence in the company’s ability to execute against its current contract portfolio.
• The Outperform initiation signals that certain analysts view Leidos’ risk and reward as attractive. Current valuation is seen as leaving scope for improved sentiment if the company meets or exceeds operational expectations.
• Bullish analysts appear to view the pressure in healthcare and defense tech as at least partly reflected in the share price. This leaves potential for upside if contract outcomes and earnings track in line with or above their assumptions.
• Supportive views on Leidos’ overall business mix, including exposure beyond healthcare, underpin the argument that earnings and cash generation could sustain the investment case if management delivers on cost control and execution.

Bearish Takeaways

• Bearish analysts cutting ratings from Buy to Neutral or Hold, with targets such as US$125 and US$140 versus prior levels of US$200 and US$185, point to a reset of expectations on valuation as they reassess growth and margin assumptions.
• There is specific concern around Leidos’ healthcare portfolio, where the Defense Health Agency’s efforts to work more directly with suppliers during the Defense Healthcare Management System Modernization maintenance phase could weigh on the company’s contract share and pricing power.
• Upcoming events like the Medical Disability Exams recompete are cited as potential pressure points that could affect future revenue visibility and margin profile if Leidos does not retain contracts on favorable terms.
• Lowered long term EPS forecasts, including a reduced FY27 EPS estimate tied to a trimmed organic growth outlook from 5% to 3%, show that some analysts are building in more conservative assumptions for Leidos’ ability to grow earnings through the current contract cycle.

What’s in the News for Leidos Holdings

• Jefferies downgraded Leidos Holdings from Buy to Hold, cut its price target from US$185 to US$140, and lowered 2027 EPS estimates, citing limited organic growth prospects, margin pressure, and uncertainty in U.S. defense budgets. The Defense Health Agency also plans to replace Leidos as primary systems integrator on the Military Health System electronic health record program by late 2026, shifting work to Oracle Health and others (source: Jefferies coverage summary).
• Leidos raised its fiscal 2026 guidance, now expecting revenue of US$18.0b to US$18.4b, and reported Q1 revenue of US$4.4b that was 2.8% above analyst expectations, alongside stronger than expected EBITDA and EPS. At the same time, the stock traded around US$114.60, down 29.3% since the earnings release and 44.3% from its 52 week high, with GF Value metrics indicating the shares were 31% to 35% below estimated intrinsic value and Wall Street consensus at a "Moderate Buy" rating (source: Q1 results and GF Value analysis).
• Bank of America Securities downgraded Leidos from Buy to Neutral, reduced its price target from US$200 to US$125, and highlighted pressure in the healthcare division, contract renewal uncertainty, program management changes, and approximately US$0.5m of insider selling without offsetting purchases (source: BofA coverage summary).
• Leidos secured four awards under the U.S. Department of State’s Evolve contract, a multiple award IDIQ with a total ceiling of US$10b. The awards cover cloud and data center services, application development, network and telecommunications, and customer and end user support, with a focus on cybersecurity, application and infrastructure modernization, and reliable IT services across the State Department’s global network (source: company client announcement).
• Leidos deployed the cloud based Joint Management Tool with the Defense Information Systems Agency and U.S. Space Command, giving operators real time visibility into global satellite communications assets and consolidating service requests into one enterprise environment. Company and Pentagon materials indicated an expected 85% reduction in command level reporting and analysis time (sources: company client announcement, Pentagon SATCOM reporting coverage).

Valuation Changes for Leidos Holdings

• Fair Value was revised slightly lower, moving from $183.27 to $178.27, reflecting more cautious assumptions in the framework for Leidos Holdings.
• The Discount Rate edged higher, shifting from 8.17% to 8.30%, which raises the required return used in the updated valuation work.
• Revenue Growth was adjusted marginally, moving from 5.52% to 5.50%, indicating only a small change to the long-term revenue growth outlook used in the model.
• The Net Profit Margin was trimmed slightly, shifting from 8.18% to 8.16%, signaling a modestly more conservative view on Leidos Holdings’ long-term earnings efficiency.
• The Future P/E was marked down modestly, moving from 16.44x to 16.10x, implying a lower valuation multiple applied to projected earnings in the updated framework.